189269-11-2Relevant academic research and scientific papers
Heterocyclic compounds as bradykinin antagonists
-
Page column 52, (2010/02/04)
This invention relates to a compound of the formula: wherein A1is lower alkylene, R1is substituted quinolyl, etc., R2is hydrogen, halogen or lower alkyl, R3is halogen or lower alkyl, and R4is a group
Quinoline derivatives as bradykinin agonists
-
, (2008/06/13)
PCT No. PCT/JP97/00233 Sec. 371 Date Aug. 3, 1998 Sec. 102(e) Date Aug. 3, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28153 PCT Pub. Date Aug. 7, 1997This invention relates to a compound of formula (1) wherein R1 is halogen, etc., R2 is halogen, etc., R3 is amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, etc., R4 is heterocyclic (lower)alkyl, R5 is lower alkyl, and A1 is lower alkylene, and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.
Heterocyclic compounds as bradykinin antagonists
-
, (2008/06/13)
This invention relates to a compound of formula (I) wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a gr
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Inamura, Noriaki,Asano, Masayuki,Aramori, Ichiro,Hatori, Chie,Sawai, Hiroe,Oku, Teruo,Tanaka, Hirokazu
, p. 4587 - 4598 (2007/10/03)
In recent articles we reported the identification of a series of 8- [[2,6-dichloro-3-[N-methyl-N-[(E)- (substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2- a]pyridines as the first orally active non-peptide bradykinin (BK) B2 rece
